Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of DC-806 in healthy participants and plaque psoriasis
NCT06808815Phase 1Completed
- Sponsor
- DICE Therapeutics
- Start
- Sep 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of navepdekinra in plaque psoriasis (6 arms), sponsored by DICE Therapeutics. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug at 11 weeks. Started Sep 2021; status: completed.
02
Drugs
navepdekinra
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06808815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06808815.